In Brief: Elcelyx splits business, Hi-Tech quarterly results, e-cigarettes study, FDA warning letters
This article was originally published in The Tan Sheet
Executive Summary
Elcelyx spins out weight-loss supplement; Hi-Tech OTCs get boost from Mag-Ox; e-cigarettes effectively help smokers quit; Irenda “use by” dates require support, FDA says; FDA warns Metagenics over medical food claims; McNeil recalls Motrin product; FDA approves Perrigo’s bubble gum version of Zyrtec.
You may also be interested in...
Hi-Tech Deal Broadens Akorn Consumer Business
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
Elcelyx Continues Work On Weight Loss Supplement With $7 Mil. Financing
The Series B funding enables the San Diego biotech to advance a weight loss supplement to the cusp of commercialization. Elcelyx, also moving a delayed-release formulation of diabetes drug metformin into mid-stage trials, so far has received some $20 million in venture capital.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”